WHO approved more hepatitis direct-acting antivirals (DAAs) for the treatment of infection with the hepatitis C virus (HCV) by 2020 which helped low- and middle-income countries increase the number of registered treatments, reduce prices of a full treatment under US$100 – update is as low as US$60 for three months, and strive towards hepatitis C elimination.
MÁS INFORMACIÓN: https://www.who.int/publications/i/item/9789240019003
